Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate.
- Author:
Jian-hua ZHU
1
;
Qiu-wen LI
;
Wen-hua XIAO
;
Jun-zhong SUN
;
Ru-liang WANG
;
Jiang-yang LU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Agents; adverse effects; therapeutic use; Benzamides; Dermatofibrosarcoma; drug therapy; metabolism; pathology; Edema; chemically induced; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Nausea; chemically induced; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; chemically induced; Piperazines; adverse effects; therapeutic use; Proto-Oncogene Proteins c-kit; metabolism; Pyrimidines; adverse effects; therapeutic use; Receptors, Platelet-Derived Growth Factor; metabolism; Remission Induction; Skin Neoplasms; drug therapy; metabolism; pathology; Survival Rate; Vomiting; chemically induced
- From: Chinese Journal of Oncology 2011;33(6):470-472
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy, side effects and toxicity of imatinib mesylate in the treatment of patients with locally advanced and/or metastatic dermatofibrosarcoma protuberans (DFSP).
METHODSTwenty-four cases of advanced DFSP diagnosed by pathology and treated in our hospital from Nov. 2004 to Oct. 2009 were included in this study. The patients were treated with imatinib mesylate (dosage: 400 mg, po, qd) and carefully observed for treatment efficacy, side effects and survival time. There were 2 patients taking the drug as second line therapy, and other 22 patients as third or more than third line therapy.
RESULTSThe 24 patients were evaluable for the efficacy. There were 8 patients (33.3%) with CR, 10 pts (41.7%) PR, 2 patients (8.3%) SD, and 4 patients (16.7%) PD. The disease control rate (DCR = CR+PR+SD) was 83.3%. The median response time in 18 cases with CR and PR was 5.6 months. The median survival time in 20 cases with disease control was 30 months, however, that in nonresponse (PD) cases was only 10 months. Side reactions related to imatinib mesylate included nausea and vomiting (20.8%), neutropenia (12.5%), and edema (8.3%).
CONCLUSIONSOur results are consistent with previous reports in the literature. Imatinib is a safe and effective moleucular target drug used for Chinese. Only mild adverse reactions occur in the treated patients. It is worth using imatinib in the treatment of advanced DFSP patients.
